Research programme: ear and nose disorder therapeutics - Auris MedicalAlternative Names: AM 123; AM-102 - Auris Medical
Latest Information Update: 27 Oct 2015
At a glance
- Originator Auris Medical; Kings College London
- Developer Auris Medical
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Nose disorders; Tinnitus